Nucleus Genomics
Best polished UX in the category, but increasingly reproductive-screening led. Nucleus sequences on Illumina's newest instrument, ships the cleanest consumer app we've seen, and keeps reports fresh via a $39/yr membership. What has shifted since last issue is the marketing: future-child health, embryo analysis, and IVF add-ons are now front-and-center. That reproductive framing is the company's single biggest differentiator and also its single biggest ethical liability, and a reader who buys Nucleus should buy it with eyes open on both counts. Kian Sadeghi, founder. Raised $14M Series A in Jan 2025. Our review covers all eight dimensions we test — from coverage depthcoverageHow many times, on average, each base is read. 30× is the consumer standard; 100× is used for hard-to-call variants and some cancer assays; 1× (low-pass) is suitable for genealogy but not for clinical variant calls. to clinical reporting quality — based on kits purchased with reader-supported funds, timed turnarounds across six orders, and an independent check of raw read filesFASTQRaw sequencing read file. The unprocessed output of the sequencer..
- ＋Sequenced on Illumina's newest NovaSeq X Plus via official partnership
- ＋Cleanest modern consumer UI in the category
- ＋170+ condition reports, refreshed against current science via the $39/yr membership
- ＋US sequencing and storage
- —Marketing now leads with future-child, embryo, and IVF products — a meaningful ethical shift that has drawn criticism from genetics ethicists
- —Polygenic risk marketing continues to compress probability estimates into diagnosis-looking claims
- —Shorter operational track record than the legacy clinical players
- —Membership model adds a recurring cost many first-time buyers don't expect
Pricing & coverage tiers
| Tier | Coverage | Price | Best for |
|---|---|---|---|
| Nucleus Core | 30× | $499 | Consumer standard |
| Membership (per year) | n/a | $39 | Interpretation only |
- 170+ health conditions
- Polygenic risk scores for 20+ diseases
- Pharmacogenomic variants
- Carrier status
- Embryo analysis (IVF add-on)
- Future-child health projections
US-based storage; standard encryption; company policy commits to no third-party data sales
The Nucleus dossier, based on public information.
Template narrative · pending independent testing
Nucleus Genomics sits in the consumer whole genome sequencingWGSWhole Genome Sequencing — reading (nearly) all 3 billion base pairs of your DNA, as opposed to genotyping arrays which sample ~600,000 known positions. market at a price point of $499. Sequencing runs on short-read on illumina novaseq x plus (official illumina partnership, us-sequenced). Company's public turnaround claim: 4–6 weeks. This section renders a structured summary from public information until our reader-supported testing cycle publishes.
Raw files — BAMBAMAligned reads mapped to a reference genome. The typical intermediate file., FASTQFASTQRaw sequencing read file. The unprocessed output of the sequencer., VCFVCFVariant Call Format — the compact list of positions where your genome differs from the reference. — are available to customers. Best polished UX in the category, but increasingly reproductive-screening led. Our editorial verdict at a glance: Best polished UX in the category, but increasingly reproductive-screening led. Nucleus sequences on Illumina's newest instrument, ships the cleanest consumer app we've seen, and keeps reports fresh via a $39/yr membership. What has shifted since last issue is the marketing: future-child health, embryo analysis, and IVF add-ons are now front-and-center. That reproductive framing is the company's single biggest differentiator and also its single biggest ethical liability, and a reader who buys Nucleus should buy it with eyes open on both counts.
The documented weak spots are marketing now leads with future-child, embryo, and ivf products — a meaningful ethical shift that has drawn criticism from genetics ethicists, and membership model adds a recurring cost many first-time buyers don't expect. Neither is necessarily a deal-breaker, but both are worth weighing before you click buy.
Editors can replace this template with a full narrative in the Payload admin: Collections → Companies → Nucleus Genomics → Full review (company detail page).